This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of -2.13% and -37.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Intra-Cellular Therapies (ITCI) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
Intra-Cellular (ITCI) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Intra-Cellular (ITCI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
How Intra-Cellular Therapies (ITCI) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Intra-Cellular Therapies (ITCI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Implied Volatility Surging for Intra-Cellular Therapies (ITCI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
Intra-Cellular Therapies' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Intra-Cellular Therapies
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 25.51% and -38.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies (ITCI): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Intra-Cellular Therapies (ITCI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Why Intra-Cellular Therapies (ITCI) Might Surprise This Earnings Season
by Zacks Equity Research
Intra-Cellular Therapies (ITCI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What Awaits Intra-Cellular Therapies (ITCI) in Q4 Earnings?
by Zacks Equity Research
Intra-Cellular Therapies (ITCI) is likely to provide update on its commercialization plan for Caplyta, approved for treating schizophrenia in December 2019, on the Q4 call.
Implied Volatility Surging for Intra-Cellular (ITCI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Intra-Cellular (ITCI) stock based on the movements in the options market lately.
Top Ranked Momentum Stocks to Buy for January 10th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 10th
Moving Average Crossover Alert: Intra-Cellular Therapies
by Zacks Equity Research
Intra-Cellular Therapies, Inc. (ITCI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Company News For Dec 24, 2019
by Zacks Equity Research
Companies in the news are: ACB, APA, ITCI, SRPT
Is the Options Market Predicting a Spike in Intra-Cellular Therapies (ITCI) Stock?
by Zacks Equity Research
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
Intra-Cellular Therapies (ITCI) in Focus: Stock Moves 6.1% Higher
by Zacks Equity Research
Intra-Cellular Therapies (ITCI) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Options Traders Expect Huge Moves in Intra-Cellular Therapies (ITCI) Stock
by Zacks Equity Research
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
Top Ranked Momentum Stocks to Buy for November 11th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 11th
Intra-Cellular Therapies Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Intra-Cellular Therapies.
Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock?
by Zacks Equity Research
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day
by Kinjel Shah
Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.
Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded
by Zacks Equity Research
Key highlights of the past week include earnings update, collaborations and other pipeline news.
Company News For Jul 9, 2019
by Zacks Equity Research
Companies in the news are: AZZ, ITCI, DB and CTST
Intra-Cellular Therapies' Candidate Fails in Phase III Study
by Zacks Equity Research
Intra-Cellular Therapies' (ITCI) lead candidate fails to meet primary endpoint in one of the phase III studies evaluating it in bipolar depression patients. Shares fall.
Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock?
by Zacks Equity Research
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.